Tarsus Pharmaceuticals, Inc.(TARS)Earnings, Financials & Key RatiosTarsus Pharmaceuticals, Inc. (TARS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while revenue growth of 106.9% is impressive, the company's inability to consistently generate positive free cash flow, evidenced by the $30.5 million outflow in 2026Q1, warrants a cautious approach.
Tarsus Pharmaceuticals, Inc. (TARS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Tarsus Pharmaceuticals, Inc. (TARS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.16vs $0.40+60.2% | $162Mvs $150M+8.3% |
| Q1 2026 | Feb 23, 2026 | $0.20vs $0.10-94.2% | $152Mvs $145M+4.9% |
| Q4 2025 | Nov 4, 2025 | $0.30vs $0.35+14.3% | $119Mvs $145M-17.9% |
| Q3 2025 | Aug 6, 2025 | $0.48vs $0.33-45.5% | $103Mvs $113M-9.2% |
Recent stock market news and headlines for Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Key metrics vs top competitors for Tarsus Pharmaceuticals, Inc. (TARS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $60.89 | $2.62B | -38.30 | 146.71% | -14.72% | -23.39% | — | |
| $103.41 | $6.73B | 30.33 | 0.5% | 18.05% | 24.33% | — | |
| $123.77 | $9.1B | -21.16 | — | — | -42.78% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $7.41 | $92.58M | -29.64 | 14.52% | -9.05% | -70.95% | — | |
| $5.62 | $232.65M | -5.92 | -3.89% | -36.58% | -17.01% | — |
Tarsus Pharmaceuticals, Inc. (TARS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Tarsus Pharmaceuticals, Inc. (TARS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
Feb 23, 2026·SEC
Feb 18, 2026·SEC
Get notified when TARS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tarsus Pharmaceuticals, Inc. (TARS) stock FAQ — growth, dividends, profitability & financials explained
Tarsus Pharmaceuticals, Inc. (TARS) reported $535.1M in revenue for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. (TARS) grew revenue by 146.7% over the past year. This is strong growth.
Tarsus Pharmaceuticals, Inc. (TARS) reported a net loss of $48.3M for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. (TARS) has a return on equity (ROE) of -23.4%. Negative ROE indicates the company is unprofitable.
Tarsus Pharmaceuticals, Inc. (TARS) had negative free cash flow of $31.5M in fiscal year 2025, likely due to heavy capital investments.
